Inhibition of MST3, a STE20-type kinase, alleviates metabolic dysfunction-related steatohepatitis in mice without influencing the development of hepatocellular carcinoma - Takeaways - MDSpire

Inhibition of MST3, a STE20-type kinase, alleviates metabolic dysfunction-related steatohepatitis in mice without influencing the development of hepatocellular carcinoma

  • By

  • Jingjing Zhang

  • Xiangdong Gongye

  • Lohitesh Kovooru

  • Emma Andersson

  • Bernice Asiedu

  • Manoj Amrutkar

  • Nadia Gul

  • Caitlyn Myers

  • Sheri Booten

  • Dan Emil Lind

  • Ying Xia

  • Antonio Molinaro

  • Anetta Härtlova

  • Per Lindahl

  • Sue Murray

  • Margit Mahlapuu

  • March 24, 2026

  • 0 min

Share

  • 1

    MST3 inhibition alleviates metabolic dysfunction-related steatohepatitis (MASH) in mice without affecting hepatocellular carcinoma development.

  • 2

    MST3, MST4, and STK25 are key drivers of hepatocellular steatotoxicity, correlating with MASH severity in human liver biopsies.

  • 3

    Inhibition of MST3 or STK25 in mice reduces hepatic steatosis, inflammation, and fibrosis associated with diet-induced MASH.

  • 4

    MST3-targeting antisense oligonucleotide improves metabolic profiles but does not impact tumor burden in MASH-associated HCC.

  • 5

    GCKIII kinases, including MST3, may play an oncogenic role in HCC development in the context of metabolic dysfunction.

Original Source(s)

Inhibition of MST3, a STE20-type kinase, alleviates metabolic dysfunction-related steatohepatitis in mice without influencing the development of hepatocellular carcinoma

  • by Jingjing Zhang, Xiangdong Gongye, Lohitesh Kovooru, Emma Andersson, Bernice Asiedu, Manoj Amrutkar, Nadia Gul, Caitlyn Myers, Sheri Booten, Dan Emil Lind, Ying Xia, Antonio Molinaro, Anetta Härtlova, Per Lindahl, Sue Murray, Margit Mahlapuu

  • March 24, 2026

Related Content

Covert hepatic encephalopathy as a multi-organ syndrome: the gut–liver–muscle–brain axis, diagnosis, treatment, and multidisciplinary care

Editorial: Metabolic and biomechanical factors in bone fragility: new frontiers in understanding and managing osteoporosis

Schisandra chinensis Fructus and its active metabolites for the treatment of metabolic dysfunction-associated steatotic liver disease